Literature DB >> 7173294

Kinetics of ergotamine after intravenous and intramuscular administration to migraine sufferers.

J J Ibraheem, L Paalzow, P Tfelt-Hansen.   

Abstract

The kinetics of ergotamine has been investigated in migrainous patients using a new, specific, sensitive HPLC assay (detection limit 100 pg/ml plasma). 10 patients were given ergotamine tartrate 0.5 mg i.v. and 5 of them received the same dose i.m. 2-3 weeks later. Blood samples were collected for up to 54 h following administration and the plasma concentration were analysed. After intravenous administration the plasma ergotamine declined rapidly, with and initial distribution half-life of 3 min followed by a mean terminal half-life of 1.86 h (range 90-155 min). The mean total plasma clearance was 11.0 ml kg-1 min-1, and the volume of distribution (Vd beta) was 1847.6 ml kg-1. Individual t1/2 beta showed a positive linear correlation with the individual Vd beta. The intramuscular absorption of ergotamine was rapid and maximum plasma levels were usually obtained 10 min following administration. The biological availability was incomplete and variable at 46.6% (range 28.3-60.8%).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7173294     DOI: 10.1007/bf00547560

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Further observations in craniovascular studies.

Authors:  P BRAZIL; A P FRIEDMAN
Journal:  Neurology       Date:  1957-01       Impact factor: 9.910

2.  Human plasma levels of some anti-migraine drugs.

Authors:  J Meier; E Schreier
Journal:  Headache       Date:  1976-07       Impact factor: 5.887

3.  Systemic availability of ergotamine tartrate after three successive doses and during continuous medication.

Authors:  V Ala-Hurula; V V Myllylä; P Arvela; N T Kärki; E Hokkanen
Journal:  Eur J Clin Pharmacol       Date:  1979-11       Impact factor: 2.953

4.  9-10-dihydroergotamine: production of antibodies and radioimmunoassay.

Authors:  J Rosenthaler; H Munzer
Journal:  Experientia       Date:  1976-02-15

5.  Specific radioimmunoassay of ergot peptide alkaloids in plasma.

Authors:  H F Schran; H J Schwarz; K C Talbot; L J Loeffler
Journal:  Clin Chem       Date:  1979-11       Impact factor: 8.327

6.  Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man.

Authors:  W H Aellig; E Nüesch
Journal:  Int J Clin Pharmacol Biopharm       Date:  1977-03

7.  Methylergometrine (methylergonovine) concentrations in the human plasma and urine.

Authors:  R Mäntylä; T Kleimola; J Kanto
Journal:  Int J Clin Pharmacol Biopharm       Date:  1978-06

8.  Systemic availability of ergotamine tartrate after oral, rectal and intramuscular administration.

Authors:  V Ala-Hurula; V V Myllylä; P Arvela; J Heikkilä; N Kärki; E Hokkanen
Journal:  Eur J Clin Pharmacol       Date:  1979-02-19       Impact factor: 2.953

9.  The effect of single dose ergotamine tartrate on peripheral arteries in migraine patients: methodological aspects and time effect curve.

Authors:  P Tfelt-Hansen; J H Eickhoff; J Olesen
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1980-08

10.  Effect of ergotamine and ergometrine on forearm venous compliance in man.

Authors:  O G Brooke; B F Robinson
Journal:  Br Med J       Date:  1970-01-17
View more
  4 in total

Review 1.  Clinical pharmacokinetics of ergotamine in migraine and cluster headache.

Authors:  V L Perrin
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

2.  Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers.

Authors:  J J Ibraheem; L Paalzow; P Tfelt-Hansen
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

3.  Ergotamine, flunarizine and sumatriptan do not change cerebral blood flow velocity in normal subjects and migraneurs.

Authors:  H C Diener; C Peters; M Rudzio; A Noe; J Dichgans; R Haux; R Ehrmann; P Tfelt-Hansen
Journal:  J Neurol       Date:  1991-08       Impact factor: 4.849

4.  Linear pharmacokinetics of intravenous ergotamine tartrate.

Authors:  J J Ibraheem; L Paalzow; P Tfelt-Hansen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.